regulatory schedule raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-20 and is reviewed periodically as new material appears.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
== Literatur == Karsten Strey: Die Welt der polycyclischen Aromaten. Lehmanns Media, Berlin 2007, ISBN 978-3-86541-184-6. Maximilian Zander: Polycyclische Aromaten – Kohlenwasserstoffe und Fullerene. Teubner Verlag, 1995, ISBN 3-519-03537-5. Michael Herrenbauer: Biosorption von Polyzyklischen Aromatischen Kohlenwasserstoffen (PAK) an Mikroorganismen und Liposomen. Shaker Verlag, 2002, ISBN 3-8265-9903-9. Tilman Gocht, Peter Gratwohl: Polyzyklische aromatische Kohlenwasserstoffe aus diffusen Quellen. Atmosphärische Deposition und Anreicherung in Böden des ländlichen Raums. In: Umweltwissenschaften und Schadstoffforschung – Zeitschrift für Umweltchemie und Ökotoxikologie. Band 16, Nr. 4, 2004, S. 245–254; doi:10.1007/BF03039576. Ronald G. Harvey: Polycyclic Aromatic Hydrocarbons. Wiley-VCH, 1997, ISBN 0-471-18608-2. C. Glende: Synthese und Mutagenitätsuntersuchungen von Derivaten des Pyrens, 1-Nitropyren und 1-Aminopyrens. Cuvillier Verlag, Göttingen 2001, ISBN 3-89873-327-0. Andreas Luch: The Carcinogenic Effects of Polycyclic Aromatic Hydrocarbons. Imperial College Press, 2005, ISBN 1-86094-417-5. Wolfgang Mücke (Hrsg.): Analytik und Mutagenität von verkehrsbedingtem Feinstaub: PAK und Nitro-PAK. Herbert Utz Verlag, München 2009, ISBN 978-3-8316-0941-3. M. T. Wu, T. C. Lee u. a.: Whole Genome Expression in Peripheral-Blood Samples of Workers Professionally Exposed to Polycyclic Aromatic Hydrocarbons. In: Chemical Research in Toxicology. Band 24, Nr. 10, 2011, S. 1636–1643, doi:10.1021/tx200181q. PMID 21854004.
== Weblinks == Polycyclische Aromatische Kohlenwasserstoffe (PAH) [MAK Value Documentation in German language, 2008]. In: The MAK-Collection for Occupational Health and Safety. Wiley-VCH Verlag, Weinheim 31. Januar 2012, S. 1–210, doi:10.1002/3527600418.mb0223orgd0045. Stiftung Warentest: FAQ PAK: Das müssen Sie über diese Schadstoffe wissen vom 5. Februar 2018 mtm ingenieurgemeinschaft: Hinweise für die Bewertung und Maßnahmen zur Verminderung der PAK-Belastung durch Parkettböden mit Teerklebstoffen in Gebäuden arguk.de: PAK im Innenraum (Memento vom 6. September 2012 im Internet Archive) BfR: Polyzyklische aromatische Kohlenwasserstoffe (PAK) in Spielzeug (PDF; 135 kB), aktualisierte Stellungnahme Nr. 051/2009 des BfR vom 14. Oktober 2009 Bundesamt für Gesundheit: Polyzyklische aromatische Kohlenwasserstoffe (PAK)
Chemische Ionisation bei Atmosphärendruck (englisch atmospheric pressure chemical ionization, APCI) ist ein Ionisierungsverfahren, das in Massenspektrometern in der Regel bei der Kopplung mit der HPLC verwendet wird. Es ist eine Form der chemischen Ionisierung bei atmosphärischem Druck und wurde 1974 durch Evan C. Horning entwickelt. Die APCI-Methode ist auch für Analyten recht gut geeignet, die weniger polar sind.
Sources: de.wikipedia.org
== Ausführung == Eine Lösung des Analyten wird durch eine Kapillare in einem Stickstoffstrom zerstäubt, wobei ein Aerosol entsteht. Dieses wird durch eine beheizte Keramik (300–600 °C) geführt, wo das Lösungsmittel vollständig verdampft wird. Der austretende Dampf wird durch Anlegen einer Hochspannung (ca. 5 kV) über eine nadelförmige Elektrode (sog. Koronanadel, engl. corona discharge needle) in ein Plasma überführt. In dem Plasma werden zunächst aus dem Lösungsmittel und eventuell zugesetztem Puffer (häufig Ammoniumacetat) Ionen gebildet. Die ionisierten Lösungsmittelmoleküle wiederum ionisieren die Analytmoleküle, die dann in die eigentliche Messapparatur überführt werden. Es kommt also zur Ionisation von Stickstoffmolekülen, die dann in einer Reaktionskaskade schlussendlich protonierte Wassercluster bilden, die dann einen Protonen-transfer auf die Analytmoleküle durchführen können. In Abhängigkeit von Lösungsmittel und Analyt sind folgende Reaktionen möglich:
Sources: de.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.